- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Oncology
Volume 2010 (2010), Article ID 396286, 13 pages
Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound
1Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
2Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
3Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
4Department of Cancer Prevention & Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Received 25 December 2009; Accepted 22 January 2010
Academic Editor: Arkadiusz Dudek
Copyright © 2010 Youcef M. Rustum et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- P. Savage, J. Stebbing, M. Bower, and T. Crook, “Why does cytotoxic chemotherapy cure only some cancers?” Nature Clinical Practice Oncology, vol. 6, no. 1, pp. 43–52, 2009.
- O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock, “Drug resistance and the solid tumor microenvironment,” Journal of the National Cancer Institute, vol. 99, no. 19, pp. 1441–1454, 2007.
- P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000.
- R. K. Jain, “Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy,” Nature Medicine, vol. 7, no. 9, pp. 987–989, 2001.
- A. Bhattacharya, M. Seshadri, S. D. Oven, K. Tóth, M. M. Vaughan, and Y. M. Rustum, “Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs,” Clinical Cancer Research, vol. 14, no. 12, pp. 3926–3932, 2008.
- A. Bhattacharya, K. Tóth, R. Mazurchuk, et al., “Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy,” Clinical Cancer Research, vol. 10, no. 23, pp. 8005–8017, 2004.
- A. Bhattacharya, K. Tóth, A. Sen, et al., “Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor,” Clinical Colorectal Cancer, vol. 8, no. 3, pp. 155–162, 2009.
- S. Cao, F. A. Durrani, and Y. M. Rustum, “Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts,” Clinical Cancer Research, vol. 10, no. 7, pp. 2561–2569, 2004.
- A. Bhattacharya, K. Tóth, F. A. Durrani, et al., “Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma A253 xenografts,” Neoplasia, vol. 10, no. 8, pp. 857–865, 2008.
- M. M. Vaughan, K. Tóth, S. Chintala, and Y. M. Rustum, “Double immunohistochemical staining method for HIF-1a and its regulators PHD2 and PHD3 in formalin fixed paraffin embedded tissues,” Applied Immunohistochemistry and Molecular Morphology, 2010.
- F. Demsar, T. P. L. Roberts, H. C. Schwickert, et al., “A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution,” Magnetic Resonance in Medicine, vol. 37, no. 2, pp. 236–242, 1997.
- M. Seshadri, R. Mazurchuk, J. A. Spernyak, A. Bhattacharya, Y. M. Rustum, and D. A. Bellnier, “Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts,” Neoplasia, vol. 8, no. 7, pp. 534–542, 2006.
- U. Ozerdem and A. R. Hargens, “A simple method for measuring interstitial fluid pressure in cancer tissues,” Microvascular Research, vol. 70, no. 1-2, pp. 116–120, 2005.
- C.-H. Heldin, K. Rubin, K. Pietras, and A. Ostman, “High interstitial fluid pressure—an obstacle in cancer therapy,” Nature Reviews Cancer, vol. 4, no. 10, pp. 806–813, 2004.
- B. D. Curti, W. J. Urba, W. G. Alvord, et al., “Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment,” Cancer Research, vol. 53, no. 10, pp. 2204–2207, 1993.
- F. G. Herrera, P. Chan, C. Doll, et al., “A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 1, pp. 97–103, 2007.
- E. Brambilla, D. Moro, S. Gazzeri, et al., “Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma,” Journal of Clinical Oncology, vol. 9, no. 1, pp. 50–61, 1991.
- R. G. Azrak, S. Cao, H. K. Slocum, et al., “Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts,” Clinical Cancer Research, vol. 10, no. 3, pp. 1121–1129, 2004.
- C. A. Kanashiro, A. V. Schally, M. Zarandi, B. D. Hammann, and J. L. Varga, “Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling,” International Journal of Cancer, vol. 112, no. 4, pp. 570–576, 2004.
- A. Mayer, M. Höckel, and P. Vaupel, “Carbonic anhydrase IX expression end tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix,” Clinical Cancer Research, vol. 11, no. 20, pp. 7220–7225, 2005.
- D. Hedley, M. Pintilie, J. Woo, et al., “Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas,” Clinical Cancer Research, vol. 9, no. 15, pp. 5666–5674, 2003.
- S. Kaluz, M. Kaluzová, S.-Y. Liao, M. Lerman, and E. J. Stanbridge, “Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?” Biochimica et Biophysica Acta, vol. 1795, no. 2, pp. 162–172, 2009.
- H. M. W. Verheul and H. M. Pinedo, “Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition,” Nature Reviews Cancer, vol. 7, no. 6, pp. 475–485, 2007.
- L. M. Ellis and D. A. Reardon, “Cancer: the nuances of therapy,” Nature, vol. 458, no. 7236, pp. 290–292, 2009.
- M. Paez-Ribes, E. Allen, J. Hudock, et al., “Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis,” Cancer Cell, vol. 15, no. 3, pp. 220–231, 2009.
- M.-B. Yin, Z.-R. Li, K. Tóth, et al., “Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1 expression, resulting in reduced angiogenesis,” Oncogene, vol. 25, no. 17, pp. 2509–2519, 2006.
- P. D. Whanger, “Selenium and its relationship to cancer: an update,” The British Journal of Nutrition, vol. 91, no. 1, pp. 11–28, 2004.
- S. Chintala, K. Tth, S. Cao, et al., “Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1,” Cancer Chemotherapy and Pharmacology, 2010.
- M. I. Jackson and G. F. Combs Jr., “Selenium and anticarcinogenesis: underlying mechanisms,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 11, no. 6, pp. 718–726, 2008.
- M. G. Fakih, L. Pendyala, W. Brady, et al., “A phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 3, pp. 499–508, 2008.